CH659585A5 - Zusammensetzung zur verringerung des augeninnendruckes. - Google Patents
Zusammensetzung zur verringerung des augeninnendruckes. Download PDFInfo
- Publication number
- CH659585A5 CH659585A5 CH1179/84A CH117984A CH659585A5 CH 659585 A5 CH659585 A5 CH 659585A5 CH 1179/84 A CH1179/84 A CH 1179/84A CH 117984 A CH117984 A CH 117984A CH 659585 A5 CH659585 A5 CH 659585A5
- Authority
- CH
- Switzerland
- Prior art keywords
- sulfonamide
- cornea
- solution
- composition
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 22
- 210000004087 cornea Anatomy 0.000 claims abstract description 22
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 22
- 239000000243 solution Substances 0.000 claims abstract description 20
- 150000003456 sulfonamides Chemical class 0.000 claims abstract description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000004410 intraocular pressure Effects 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 210000001742 aqueous humor Anatomy 0.000 claims abstract description 9
- 238000005192 partition Methods 0.000 claims abstract description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000010494 dissociation reaction Methods 0.000 claims abstract description 6
- 230000005593 dissociations Effects 0.000 claims abstract description 6
- 230000035515 penetration Effects 0.000 claims abstract description 5
- 239000003112 inhibitor Substances 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
- -1 heterocyclic sulfonamide Chemical class 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- CUKDCXMUNRKMEU-UHFFFAOYSA-N 2-(2-chlorophenyl)-3h-thiadiazole-5-sulfonamide Chemical group S1C(S(=O)(=O)N)=CNN1C1=CC=CC=C1Cl CUKDCXMUNRKMEU-UHFFFAOYSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 102000003846 Carbonic anhydrases Human genes 0.000 abstract 2
- 108090000209 Carbonic anhydrases Proteins 0.000 abstract 2
- 230000000266 injurious effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 27
- 230000000694 effects Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000010412 Glaucoma Diseases 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical group CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 229960000571 acetazolamide Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical group CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical group CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 2
- 229960004083 methazolamide Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- KIOBNZYUIQWQNP-UHFFFAOYSA-N 2,3-dihydrothiadiazole-5-sulfonamide Chemical compound NS(=O)(=O)C1=CNNS1 KIOBNZYUIQWQNP-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229950005098 ethoxzolamide Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16722080A | 1980-07-09 | 1980-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH659585A5 true CH659585A5 (de) | 1987-02-13 |
Family
ID=22606448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1179/84A CH659585A5 (de) | 1980-07-09 | 1984-03-09 | Zusammensetzung zur verringerung des augeninnendruckes. |
Country Status (15)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0245604B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1980-07-09 | 1990-10-11 | Yunibaashitei Obu Furorida Za | |
| GB2155331B (en) * | 1980-07-09 | 1988-09-01 | Florida University Of | Composition for reducing intraocular pressure |
| US5095026A (en) * | 1983-02-04 | 1992-03-10 | University Of Iowa Research Foundation | Prodrugs of carbonic anhydrase inhibitors |
| US4828545A (en) * | 1984-02-08 | 1989-05-09 | Omni-Flow, Inc. | Pressure responsive multiple input infusion system |
| US4678855A (en) * | 1985-10-09 | 1987-07-07 | Merck & Co., Inc. | Substituted benzenesulfonamides |
| US4873239A (en) * | 1987-01-29 | 1989-10-10 | Hoechst-Roussel Pharmaceuticals, Inc. | Arylthiadiazolylsulfonamides and derivatives |
| US5494901A (en) * | 1993-01-05 | 1996-02-27 | Javitt; Jonathan C. | Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent |
| US5573007A (en) * | 1994-08-08 | 1996-11-12 | Innerspace, Inc. | Gas column pressure monitoring catheters |
| FR2734581B1 (fr) | 1995-05-24 | 1997-08-14 | Europ Propulsion | Fil hybride pour la fabrication de preformes fibreuses de pieces en materiau composite et procede pour sa preparation |
| US6337340B1 (en) * | 1998-08-14 | 2002-01-08 | Gpi Nil Holdings, Inc. | Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders |
| PL218655B1 (pl) | 2009-05-05 | 2015-01-30 | Franc Gardiner Spółka Z Ograniczoną Odpowiedzialnością | Mechanizm blokujący ruch obrotowy wałka nawojowego rolety o napędzie sprężynowym, zwłaszcza rolety okiennej |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| FR2468366A1 (fr) * | 1979-10-31 | 1981-05-08 | Stoclet Alain | Medicament antiglaucomateux a base d'acetazolamide ou de methazolamide |
| JPH0245604B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1980-07-09 | 1990-10-11 | Yunibaashitei Obu Furorida Za | |
| DE3102593A1 (de) * | 1981-01-27 | 1982-09-02 | Dr. Thilo & Co GmbH, 8021 Sauerlach | Arzneimittelzubereitung zur anwendung am auge |
-
1981
- 1981-05-29 JP JP56502354A patent/JPH0245604B2/ja not_active Expired - Lifetime
- 1981-05-29 WO PCT/US1981/000719 patent/WO1982000096A1/en unknown
- 1981-06-04 IE IE1235/81A patent/IE52065B1/en not_active IP Right Cessation
- 1981-06-08 GR GR65175A patent/GR74616B/el unknown
- 1981-06-08 PT PT73152A patent/PT73152B/pt unknown
- 1981-06-09 AT AT81302561T patent/ATE13632T1/de not_active IP Right Cessation
- 1981-06-09 DE DE8181302561T patent/DE3170818D1/de not_active Expired
- 1981-06-09 EP EP81302561A patent/EP0044134B1/en not_active Expired
- 1981-06-25 CA CA000380546A patent/CA1193546A/en not_active Expired
-
1984
- 1984-03-07 SE SE8401281A patent/SE455919B/sv not_active IP Right Cessation
- 1984-03-09 FR FR8403622A patent/FR2560769B1/fr not_active Expired
- 1984-03-09 CH CH1179/84A patent/CH659585A5/de not_active IP Right Cessation
- 1984-03-14 NL NL8400804A patent/NL191879C/xx not_active IP Right Cessation
- 1984-03-16 CA CA000449853A patent/CA1192560A/en not_active Expired
- 1984-03-22 LU LU85264A patent/LU85264A1/fr unknown
- 1984-03-26 DE DE19843411104 patent/DE3411104A1/de active Granted
- 1984-04-02 BE BE0/212686A patent/BE899314A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NL8400804A (nl) | 1985-10-01 |
| DE3170818D1 (en) | 1985-07-11 |
| PT73152A (en) | 1981-07-01 |
| SE8401281L (sv) | 1985-09-08 |
| EP0044134A3 (en) | 1982-04-28 |
| NL191879C (nl) | 1996-10-04 |
| PT73152B (en) | 1987-08-17 |
| LU85264A1 (fr) | 1984-11-14 |
| SE8401281D0 (sv) | 1984-03-07 |
| EP0044134A2 (en) | 1982-01-20 |
| JPH0245604B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-10-11 |
| ATE13632T1 (de) | 1985-06-15 |
| EP0044134B1 (en) | 1985-06-05 |
| CA1192560A (en) | 1985-08-27 |
| CA1193546A (en) | 1985-09-17 |
| FR2560769A1 (fr) | 1985-09-13 |
| IE811235L (en) | 1982-01-09 |
| DE3411104A1 (de) | 1985-10-03 |
| JPS57500978A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1982-06-03 |
| FR2560769B1 (fr) | 1987-11-13 |
| GR74616B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-06-29 |
| WO1982000096A1 (en) | 1982-01-21 |
| NL191879B (nl) | 1996-06-03 |
| BE899314A (fr) | 1984-10-02 |
| SE455919B (sv) | 1988-08-22 |
| IE52065B1 (en) | 1987-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3785789T2 (de) | Apparat zur Verabreichung von Medikamenten durch Iontophorese. | |
| DE3119051A1 (de) | Mittel zur behandlung der augen | |
| DE2036114C3 (de) | Wäßriges Tetramisolpräparat | |
| US4619939A (en) | Process for reducing intraocular pressure | |
| EP0801948A1 (de) | Ophtalmische Zusammensetzung mit verlängerter Verweilzeit am Auge | |
| DD266506A5 (de) | Verfahren zur herstellung einer pharmazeutischen band-zusammensetzung | |
| DE69133341T2 (de) | Zusammensetzungen und behandlungsverfahren für sympathisch unterhaltenen schmerz | |
| CH659585A5 (de) | Zusammensetzung zur verringerung des augeninnendruckes. | |
| DE2717002A1 (de) | Dauerwell-mischung | |
| DE69015630T2 (de) | Stabile Natriumhypochloritlösung. | |
| DE69106990T2 (de) | Poviden-Jod enthaltende pharmazeutische Zubereitung. | |
| DE3882042T2 (de) | Antiallergische augentropfen. | |
| DE69917623T2 (de) | Ophthalmologische lösung enthaltend glykogen | |
| DE3819842C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2851369C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CH654205A5 (de) | Praeparat zur behandlung von glaucoma oder zur herabsetzung von intraocularem druck. | |
| DE69613803T2 (de) | Augentropfen insbesonders zur Behandlung des trockenen Auges | |
| EP0111735B1 (de) | Verfahren zur Gewinnung von Tränenflüssigkeit | |
| DE2330338A1 (de) | Okular-hypotensives mittel | |
| DE2723936A1 (de) | Ophthalmische loesung fuer die glaucom-behandlung | |
| EP0013056A2 (de) | Vaginales Kontrazeptivum | |
| DE3688503T2 (de) | Erhöhung des ausfliessens wässriger körperfluessigkeit. | |
| DE2212392C3 (de) | Verwendung von mikrokristallinem Collagen zur Herstellung eines wäßrigen pharmazeutischen Mittels für die topische Anwendung am Auge | |
| DE2410939A1 (de) | Lokalanaesthetisches mittel | |
| DE3204235C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |